GlassScriptPhysician profile
Julia Petraitis
NPI 1295108363
$9,017.73
in general payments reported to CMS, 2019-2025
39 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,130 · 2022: $1,687 · 2023: $1,710 · 2024: $1,796 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,129 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,129.14 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,560.35 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,092.96 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $922.07 | 2021 | |
| Vanda Pharmaceuticals INC. | $515.55 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $505.00 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $401.21 | 2021-2025 | Vyepti, Rexulti |
| Merck Sharp & Dohme LLC | $287.40 | 2021-2023 | Belsomra |
| Eisai INC. | $209.38 | 2021 | |
| Impel Pharmaceuticals INC. | $190.78 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $178.65 | 2021-2025 | Rexulti |
| Grt US Holding, INC. | $175.52 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.58 | 2021-2025 | Caplyta |
| Lilly USA, LLC | $171.25 | 2021-2023 | Emgality, Reyvow |
| Amgen INC. | $156.17 | 2021-2024 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $142.85 | 2021-2025 | Trintellix |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $135.13 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Pfizer INC. | $121.27 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $109.05 | 2022 | |
| Collegium Pharmaceutical, INC. | $106.91 | 2023-2025 | Belbuca, Xtampza |
| Ani Pharmaceuticals, INC. | $100.57 | 2023-2024 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $99.03 | 2021-2025 | General - Pain Management |
| Harmony Biosciences LLC | $79.06 | 2022-2023 | Wakix |
| Jazz Pharmaceuticals INC. | $68.79 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $63.73 | 2021-2022 | |
| Alkermes, INC. | $52.07 | 2025 | Aristada, Vivitrol, Lybalvi |
| Idorsia Pharmaceuticals US INC | $46.36 | 2022-2023 | Quviviq |
| Bioventus LLC | $45.92 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.98 | 2022-2023 | Invega Trinza, Spravato, Invega |
| Almatica Pharma LLC | $40.65 | 2021-2023 | Gralise |
| E.R. Squibb & Sons, L.L.C. | $35.30 | 2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $29.23 | 2024-2025 | Wainua |
| Biodelivery Sciences International, INC. | $27.29 | 2021 | |
| Si-Bone, INC. | $26.78 | 2024 | |
| Sunovion Pharmaceuticals INC. | $21.87 | 2021 | |
| Averitas Pharma INC. | $20.33 | 2024 | Qutenza |
| Xeris Pharmaceuticals, INC. | $18.95 | 2023 | Keveyis |
| Ibsa Pharma INC. | $18.30 | 2023 | Tirosint, Licart |
| Alfasigma USA, INC. | $13.96 | 2021 | |
| Pacira Therapeutics, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Petraitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.